Cocrystal Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Cocrystal Pharma
COCP Stock  USD 2.07  0.03  1.43%   
Cocrystal Pharma financial statements provide useful quarterly and yearly information to potential Cocrystal Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cocrystal Pharma financial statements helps investors assess Cocrystal Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cocrystal Pharma's valuation are summarized below:
Gross Profit
-8.8 M
Market Capitalization
21.4 M
Enterprise Value Revenue
17.8912
Revenue
510 K
Earnings Share
(1.84)
There are currently one hundred twenty fundamental signals for Cocrystal Pharma that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Cocrystal Pharma's prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 12/02/2024, Market Cap is likely to drop to about 89.4 M. In addition to that, Enterprise Value is likely to drop to about 88.5 M

Cocrystal Pharma Total Revenue

5.43 Million

Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.6. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Cocrystal Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.7 M31.3 M72.3 M
Very volatile
Total Current Liabilities2.7 M3.3 M4.1 M
Slightly volatile
Accounts Payable931.8 K1.2 M852.7 K
Pretty Stable
Cash27.7 M26.4 M14.1 M
Slightly volatile
Non Current Assets Total2.1 M2.2 M56.4 M
Pretty Stable
Cash And Short Term Investments27.7 M26.4 M14.3 M
Slightly volatile
Common Stock Total Equity152.4 K81.7 K153.6 K
Very volatile
Common Stock Shares Outstanding13.1 M9.7 M14.4 M
Slightly volatile
Liabilities And Stockholders Equity29.7 M31.3 M72.3 M
Very volatile
Total Liabilities4.6 M4.9 M26.7 M
Pretty Stable
Total Current Assets30.5 M29.1 M16 M
Slightly volatile
Common Stock9.5 K10 K136.9 K
Pretty Stable
Other Current Liabilities1.7 M1.6 M2.3 M
Slightly volatile
Property Plant And Equipment Net2.2 M2.1 M1.1 M
Very volatile
Other Current Assets948.6 K1.8 M925.5 K
Very volatile
Property Plant And Equipment Gross4.1 M3.9 M1.6 M
Slightly volatile
Short and Long Term Debt Total1.6 M1.9 M2 M
Slightly volatile
Non Current Liabilities Total1.5 M1.6 M39 M
Slightly volatile
Inventory64.1 K67.5 K391.1 K
Slightly volatile
Short Term Debt410.4 K432 K2.4 M
Slightly volatile
Intangible Assets80.6 M62 M69.1 M
Very volatile
Current Deferred Revenue897.6 K647.1 K1.1 M
Slightly volatile
Capital Surpluse215.9 M341.9 M187.1 M
Slightly volatile
Other Liabilities23.1 M15.6 M12.7 M
Slightly volatile
Long Term Debt861 K906.3 K25.7 M
Slightly volatile
Short Term Investments24.8 K26.1 K677.2 K
Slightly volatile
Long Term Debt Total12 K12.6 K25.2 M
Slightly volatile
Deferred Long Term Liabilities87.8 M48.5 M105.7 M
Slightly volatile
Long Term Investments1.9 M2.1 M2.3 M
Slightly volatile
Short and Long Term Debt861 K906.3 K3.7 M
Slightly volatile
Preferred Stock Total Equity142.6 M160.4 M174.7 M
Slightly volatile
Property Plant Equipment640.6 K708.4 K515.1 K
Slightly volatile
Net Invested Capital45.1 M26.4 M79 M
Slightly volatile
Net Working Capital25.7 M25.8 M13 M
Slightly volatile
Capital Lease Obligations1.9 M1.9 M601.4 K
Slightly volatile
Capital Stock9.5 K10 K33.5 K
Very volatile
Non Current Liabilities Other366.4 K341.1 K481 K
Slightly volatile

Cocrystal Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.1 M6 M4.5 M
Pretty Stable
Selling And Marketing Expenses8.9 M8.5 M6.2 M
Slightly volatile
Other Operating Expenses22.5 M18.6 M24.7 M
Very volatile
Cost Of Revenue15.9 M15.2 M3.4 M
Pretty Stable
Total Operating Expenses3.2 M3.4 M21.2 M
Very volatile
Research Development22.4 M15.2 M19.2 M
Pretty Stable
Preferred Stock And Other Adjustments3.3 M3.7 M4.1 M
Slightly volatile
Interest Income202.6 K213.3 K4.1 M
Slightly volatile
Reconciled Depreciation302.2 K412 K195.5 K
Slightly volatile
Non Recurring36.9 M41.5 M45.2 M
Slightly volatile

Cocrystal Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow39.1 M37.2 M13.2 M
Slightly volatile
End Period Cash Flow27.7 M26.4 M14.2 M
Slightly volatile
Stock Based Compensation1.5 M801 K2.1 M
Slightly volatile
Sale Purchase Of Stock43.2 M41.2 M15.9 M
Slightly volatile
Other Cashflows From Investing Activities1.7 M1.6 M1 M
Slightly volatile
Issuance Of Capital Stock3.4 M3.6 M10.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3834031.4 K
Pretty Stable
Days Sales Outstanding1101161.7 K
Slightly volatile
Average Payables259.8 K432.1 K431 K
Pretty Stable
Stock Based Compensation To Revenue0.360.383.2014
Pretty Stable
EV To Sales3693881.3 K
Pretty Stable
Inventory Turnover4.093.73.4745
Slightly volatile
Days Of Inventory On Hand96.88102690
Pretty Stable
Payables Turnover13.0312.41333.0883
Pretty Stable
Sales General And Administrative To Revenue2.873.0218.5358
Slightly volatile
Average Inventory954.5 K949.4 K853.6 K
Pretty Stable
Research And Ddevelopement To Revenue2.682.82102
Slightly volatile
Capex To Revenue0.10.110.4151
Pretty Stable
Cash Per Share1.992.73062.8682
Pretty Stable
Days Payables Outstanding27.9329.40413.7 K
Very volatile
Income Quality0.770.81555.1794
Pretty Stable
Intangibles To Total Assets0.210.220.5464
Pretty Stable
Current Ratio5.938.91818.605
Slightly volatile
Receivables Turnover3.964.178.6002
Slightly volatile
Graham Number10.1710.706172.7576
Slightly volatile
Capex Per Share0.01160.01220.4138
Slightly volatile
Average Receivables901.6 K780.9 K738.1 K
Pretty Stable
Revenue Per Share0.03980.041917.5732
Slightly volatile
Interest Debt Per Share0.02360.02498.6608
Slightly volatile
Debt To Assets0.00730.00770.1714
Slightly volatile
Days Of Payables Outstanding27.9329.40413.7 K
Very volatile
Ebt Per Ebit1.350.9691.2899
Slightly volatile
Total Debt To Capitalization0.00860.0090.4219
Slightly volatile
Quick Ratio5.98.91818.563
Slightly volatile
Net Income Per E B T0.971.150.9667
Pretty Stable
Cash Ratio5.538.07888.0179
Slightly volatile
Days Of Inventory Outstanding96.88102690
Pretty Stable
Days Of Sales Outstanding1101161.7 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.0081.1387
Slightly volatile
Fixed Asset Turnover3.12.133.1612
Very volatile
Debt Ratio0.00730.00770.1714
Slightly volatile
Price Sales Ratio3834031.4 K
Pretty Stable
Asset Turnover0.04060.04270.4554
Slightly volatile
Operating Cycle1511592.9 K
Pretty Stable

Cocrystal Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap89.4 M90.7 M123.4 M
Very volatile
Enterprise Value88.5 M88.6 M121.5 M
Very volatile

Cocrystal Fundamental Market Drivers

Cash And Short Term Investments26.4 M

Cocrystal Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue647.1 K897.6 K
Cost Of Revenue15.2 M15.9 M
Stock Based Compensation To Revenue 0.38  0.36 
Sales General And Administrative To Revenue 3.02  2.87 
Research And Ddevelopement To Revenue 2.82  2.68 
Capex To Revenue 0.11  0.10 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(5.47)(5.75)

Pair Trading with Cocrystal Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Cocrystal Stock

  0.65EYEN EyenoviaPairCorr
  0.54ENVB Enveric BiosciencesPairCorr
  0.51A Agilent Technologies Sell-off TrendPairCorr
  0.5FATE Fate Therapeutics TrendingPairCorr
  0.47VRPX Virpax PharmaceuticalsPairCorr
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY